Accuracy of [18F]FDG PET/MRI for the Detection of Liver Metastases

Background The aim of this study was to compare the diagnostic accuracy of [18F]FDG-PET/MRI with PET/CT for the detection of liver metastases. Methods 32 patients with solid malignancies underwent [18F]FDG-PET/CT and subsequent PET/MRI of the liver. Two readers assessed both datasets regarding lesion characterization (benign, indeterminate, malignant), conspicuity and diagnostic confidence. An imaging follow-up (mean interval: 185±92 days) and/-or histopathological specimen served as standards of reference. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for both modalities. Accuracy was determined by calculating the area under the receiver operating characteristic (ROC) curve. Values of conspicuity and diagnostic confidence were compared using Wilcoxon-signed-rank test. Results The standard of reference revealed 113 liver lesions in 26 patients (malignant: n = 45; benign: n = 68). For PET/MRI a higher accuracy (PET/CT: 82.4%; PET/MRI: 96.1%; p<0.001) as well as sensitivity (67.8% vs. 92.2%, p<0.01) and NPV (82.0% vs. 95.1%, p<0.05) were observed. PET/MRI offered higher lesion conspicuity (PET/CT: 2.0±1.1 [median: 2; range 0–3]; PET/MRI: 2.8±0.5 [median: 3; range 0–3]; p<0.001) and diagnostic confidence (PET/CT: 2.0±0.8 [median: 2; range: 1–3]; PET/MRI 2.6±0.6 [median: 3; range: 1–3]; p<0.001). Furthermore, PET/MRI enabled the detection of additional PET-negative metastases (reader 1: 10; reader 2: 12). Conclusions PET/MRI offers higher diagnostic accuracy compared to PET/CT for the detection of liver metastases.

[1]  Patrick Veit-Haibach,et al.  Protocol requirements and diagnostic value of PET/MR imaging for liver metastasis detection , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Andrea Soricelli,et al.  Clinical impact of PET/MR imaging in patients with cancer undergoing same-day PET/CT: initial experience in 134 patients--a hypothesis-generating exploratory study. , 2013, Radiology.

[3]  Felix Nensa,et al.  Depiction and characterization of liver lesions in whole body [¹⁸F]-FDG PET/MRI. , 2013, European journal of radiology.

[4]  L. Rubbia‐Brandt,et al.  Operative Management of Colorectal Liver Metastases , 2013, Seminars in Liver Disease.

[5]  D. Weishaupt,et al.  Accuracy and confidence of Gd-EOB-DTPA enhanced MRI and diffusion-weighted imaging alone and in combination for the diagnosis of liver metastases. , 2013, European journal of radiology.

[6]  Felix Nensa,et al.  Simultaneous 18F Choline Positron Emission Tomography/Magnetic Resonance Imaging of the Prostate: Initial Results , 2013, Investigative radiology.

[7]  A. Ba-Ssalamah,et al.  Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation , 2013, European Radiology.

[8]  K. Ohtomo,et al.  Detection of liver metastasis: is diffusion-weighted imaging needed in Gd-EOB-DTPA-enhanced MR imaging for evaluation of colorectal liver metastases? , 2012, Japanese Journal of Radiology.

[9]  R. Gibney,et al.  Diagnostic performance of MDCT, PET/CT and gadoxetic acid (Primovist®)-enhanced MRI in patients with colorectal liver metastases being considered for hepatic resection: initial experience in a single centre , 2012, Irish Journal of Medical Science.

[10]  William R Jarnagin,et al.  Preoperative imaging for hepatic resection of colorectal cancer metastasis. , 2012, Journal of gastrointestinal oncology.

[11]  Ernst J. Rummeny,et al.  Detection, classification, and characterization of focal liver lesions: Value of diffusion-weighted MR imaging, gadoxetic acid-enhanced MR imaging and the combination of both methods , 2012, Abdominal Imaging.

[12]  Myeong-Jin Kim,et al.  F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for the Detection of Colorectal Liver Metastases , 2011 .

[13]  Robert Dura,et al.  Dual‐time‐point 18F‐FDG‐PET/CT imaging in the assessment of suspected malignancy , 2011, Journal of medical imaging and radiation oncology.

[14]  Young Kon Kim,et al.  Detection of liver malignancy with gadoxetic acid-enhanced MRI: is addition of diffusion-weighted MRI beneficial? , 2011, Clinical radiology.

[15]  G. Jahng,et al.  The detection and discrimination of malignant and benign focal hepatic lesions: T2 weighted vs diffusion-weighted MRI. , 2011, The British journal of radiology.

[16]  N. Faccioli,et al.  Solid Hypervascular Liver Lesions: Accurate Identification of True Benign Lesions on Enhanced Dynamic and Hepatobiliary Phase Magnetic Resonance Imaging After Gadobenate Dimeglumine Administration , 2011, Investigative radiology.

[17]  Masatoshi Hori,et al.  18F-FDG PET/MRI fusion in characterizing pancreatic tumors: comparison to PET/CT , 2011, International Journal of Clinical Oncology.

[18]  J. Hornegger,et al.  Anatomische Genauigkeit der retrospektiven, automatischen und starren Bildregistrierung zwischen FDG-PET und MRI bei abdominalen Läsionen , 2011 .

[19]  J Hornegger,et al.  Anatomical accuracy of abdominal lesion localization. Retrospective automatic rigid image registration between FDG-PET and MRI. , 2011, Nuklearmedizin. Nuclear medicine.

[20]  S. Moon,et al.  Detection of Hepatic Metastases Using Dual-Time-Point FDG PET/CT Scans in Patients with Colorectal Cancer , 2011, Molecular Imaging and Biology.

[21]  Ernst J Rummeny,et al.  Characterization of small (≤10 mm) focal liver lesions: value of respiratory-triggered echo-planar diffusion-weighted MR imaging. , 2010, European journal of radiology.

[22]  G. V. von Schulthess,et al.  Value of Retrospective Fusion of PET and MR Images in Detection of Hepatic Metastases: Comparison with 18F-FDG PET/CT and Gd-EOB-DTPA–Enhanced MRI , 2010, Journal of Nuclear Medicine.

[23]  B. Nordlinger,et al.  The Role of Preoperative Chemotherapy in Patients with Resectable Colorectal Liver Metastases , 2009, Annals of Surgical Oncology.

[24]  G. Maddern,et al.  Radiofrequency ablation of liver tumors: a systematic review. , 2006, Archives of surgery.

[25]  D. Panicek,et al.  Hepatic lesions deemed too small to characterize at CT: prevalence and importance in women with breast cancer. , 2005, Radiology.

[26]  Thomas Beyer,et al.  Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  B. Siegel,et al.  Five-Year Survival After Resection of Hepatic Metastases From Colorectal Cancer in Patients Screened by Positron Emission Tomography With F-18 Fluorodeoxyglucose (FDG-PET) , 2004, Annals of surgery.

[28]  Young Kon Kim,et al.  Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions , 2004, European Radiology.

[29]  J. Debatin,et al.  Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. , 2003, JAMA.

[30]  G. Marchal,et al.  Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study. , 2000, Radiology.

[31]  L. Schwartz,et al.  Prevalence and importance of small hepatic lesions found at CT in patients with cancer. , 1999, Radiology.

[32]  R. Newcombe.  Two-sided confidence intervals for the single proportion: comparison of seven methods. , 1998, Statistics in medicine.

[33]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[34]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.